Drug search by name

Zydelig and Hepatic impairment

Result of checking the interaction of drug Zydelig and disease Hepatic impairment for safety when used together.

Check result:

Zydelig <> Hepatic impairment

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Fatal and/or serious hepatotoxicity have been reported in patients treated with idelalisib. Monitor ALT and AST in all patients as clinically appropriate. Patients with baseline hepatic impairment should be monitored for signs of idelalisib toxicity and dose modification with idelalisib should be made accordingly. It is recommended to monitor weekly for liver toxicity if the ALT or AST rises above 3 times the upper limit of normal until resolved and withhold therapy with idelalisib if the ALT or AST is greater than 5 times the upper limit of normal, and continue to monitor AST, ALT and total bilirubin weekly until the normal levels are attained. Discontinue idelalisib for recurrent hepatotoxicity and to avoid concurrent use with other drugs that may cause liver toxicity.

Zydelig

Generic Name: idelalisib

Brand Name: Zydelig

Synonyms: n.a.

What is Zydelig?